Why T2D drives liver disease
Insulin resistance is the shared mechanism. The same metabolic dysfunction that drives type 2 diabetes drives liver fat accumulation. In Australian metabolic clinic populations:
- ~65% of T2D patients have MASLD
- ~20% of T2D-MASLD patients have MASH (the inflammatory form)
- ~5–10% will progress to cirrhosis over a decade if untreated
The combination of T2D and significant liver fibrosis is the strongest predictor of liver-related mortality in metabolic populations.
Why most T2D patients aren't told about MASLD
Liver disease in T2D is silent. ALT can be normal even with significant fibrosis. Standard abdominal ultrasound may show fatty liver but doesn't stage fibrosis. Without active screening, MASLD in T2D is usually only diagnosed when it's advanced — by which point the treatment window is narrower.
Screening pathway: FIB-4 then elastography
- FIB-4 from routine LFT + platelets at any diabetes review visit
- If FIB-4 < 1.3 (or < 2.0 if 65+): annual LFTs, reassess yearly
- If FIB-4 1.3–2.67: elastography to clarify fibrosis
- If FIB-4 > 2.67: hepatology referral
GLP-1 therapy and liver outcomes in T2D
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) drive substantial improvements in liver fat, inflammation and fibrosis in T2D-MASLD patients. The ESSENCE Phase 3 trial of semaglutide for MASH produced histological resolution in 62.9% of patients. Tirzepatide trial data shows similar magnitude. The MASLD population in T2D is exactly the cohort GLP-1 therapy treats most effectively for both conditions simultaneously.
Frequently asked questions
Do I need a liver scan if I have type 2 diabetes?
If you have T2D, your GP should order a FIB-4 at any annual review. If FIB-4 is indeterminate, elastography is the next step. With 65% of T2D patients having MASLD, screening is essential.
Does Ozempic treat liver disease in diabetes?
Yes — semaglutide reduces liver fat, inflammation and fibrosis in MASLD/MASH patients. The FDA approved semaglutide for MASH in August 2025 based on ESSENCE Phase 3 data showing 62.9% histological resolution.
Can MASLD reverse with diabetes treatment?
Often yes — with weight loss, glycaemic control and (where appropriate) GLP-1 therapy. Earlier-stage disease reverses more completely. Established cirrhosis usually doesn't reverse.
How often should T2D patients monitor their liver?
Annual FIB-4 minimum. Elastography at baseline if FIB-4 is indeterminate, then every 12–24 months while at risk and on therapy.
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.
This page is educational and not medical advice. Always discuss your GLP-1 treatment and liver monitoring with your GP.